$23.45
0[0.00%]
Last update: 4:00PM Get Real Time Here
Pharvaris
(NASDAQ:PHVS)Latest News for Pharvaris Stock (NASDAQ:PHVS)
Pharvaris Stock (NASDAQ: PHVS)
Categories: All
Monday, April 22, 2024
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
- Pharvaris Q4 EPS $(0.80) Misses $(0.58) EstimateBenzinga Newsdesk - Apr 10, 2024, 5:32PM
- Pharvaris N.V. Q4 2023 EPS €(0.74) Vs €(1.16) YoY; Cash And Cash Equivalents Were ~€391 Million As Of December 31, 2023Benzinga Newsdesk - Apr 10, 2024, 4:14PM
- Pharvaris Appoints David Nassif As CFOBenzinga Newsdesk - Apr 10, 2024, 4:09PM
Tuesday, March 19, 2024
Wednesday, March 06, 2024
Thursday, February 22, 2024
Wednesday, February 14, 2024
Tuesday, January 23, 2024
Monday, January 22, 2024
- FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock JumpsVandana Singh - Jan 22, 2024, 12:28PM
- Pharvaris shares are trading higher after the company announced the FDA lifted the clinical hold on the IND application for deucrictibant for the prophylactic treatment of HAE attacks following review of data from a 26-week rodent toxicology study.Benzinga Newsdesk - Jan 22, 2024, 9:12AM
- The FDA Has Lifted The Clinical Hold On Pharvaris' Investigational New Drug Application For Deucrictibant For Prophylactic Treatment Of Hereditary Angioedema Attacks Following The Review Of Data From A 26-week Rodent Toxicology StudyBenzinga Newsdesk - Jan 22, 2024, 6:52AM
Thursday, December 07, 2023
- B of A Securities Maintains Underperform on Pharvaris, Raises Price Target to $11Benzinga Newsdesk - Dec 7, 2023, 4:07PM
- Analyst Expectations for Pharvaris's FutureBenzinga Insights - Dec 7, 2023, 9:00AM
- Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $35Benzinga Newsdesk - Dec 7, 2023, 8:02AM
Wednesday, December 06, 2023
- Gold Moves Higher; Campbell Soup Earnings Top ExpectationsLisa Levin - Dec 6, 2023, 2:45PM
- Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Dec 6, 2023, 2:43PM
- Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts AttacksVandana Singh - Dec 6, 2023, 12:46PM
- Crude Oil Down 4%; Pharvaris Shares Spike HigherLisa Levin - Dec 6, 2023, 12:29PM
- THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On WednesdayLisa Levin - Dec 6, 2023, 10:48AM
- US Stocks Higher; Private Payrolls Rise By 103,000 In NovemberLisa Levin - Dec 6, 2023, 9:42AM
- Pharvaris shares are trading higher after the company announced the CHAPTER-1 Phase 2 clinical study met its primary endpoint.Benzinga Newsdesk - Dec 6, 2023, 9:09AM
- Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants; Offering Is Expected To Close On Or About December 8, 2023Benzinga Newsdesk - Dec 6, 2023, 7:24AM
- Pharvaris Announces Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksBenzinga Newsdesk - Dec 6, 2023, 6:50AM
Tuesday, November 14, 2023
Thursday, November 09, 2023
Friday, November 03, 2023
Monday, September 25, 2023
- Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% UpsideVandana Singh - Sep 25, 2023, 3:47PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023Benzinga Insights - Sep 25, 2023, 11:00AM
- Wedbush Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $27Benzinga Newsdesk - Sep 25, 2023, 8:11AM
Monday, September 11, 2023
Friday, August 18, 2023
Tuesday, August 15, 2023
- Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Aug 15, 2023, 2:01PM
- Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023Benzinga Insights - Aug 15, 2023, 11:00AM
- Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On TuesdayLisa Levin - Aug 15, 2023, 10:42AM
- Pharvaris shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $10 to $34.Benzinga Newsdesk - Aug 15, 2023, 8:50AM
- 8 Analysts Have This to Say About PharvarisBenzinga Insights - Aug 15, 2023, 8:00AM
- Morgan Stanley Upgrades Pharvaris to Overweight, Raises Price Target to $34Benzinga Newsdesk - Aug 15, 2023, 5:20AM